Education
About Us
Working with TipRanks
Follow Us
Windtree Therapeutics (WINT)
OTHER OTC:WINT
WINT Stock Chart & Stats
$0.03
-$0.02(-5.33%)
At close: 4:00 PM EST
$0.03
-$0.02(-5.33%)
Day’s Range― - ―
52-Week Range<$0.01 - $3.48
Previous CloseN/A
Volume14.98M
Average Volume (3M)403.29K
Market Cap
$444.96K
Enterprise Value$13.17M
Total Cash (Recent Filing)$204.00K
Total Debt (Recent Filing)$12.93M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Apr 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding33,708,782
10 Day Avg. Volume496,404
30 Day Avg. Volume403,289
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.06
Enterprise Value/Market Cap29.60
Enterprise Value/Revenue146.32
Enterprise Value/Gross Profit1.20K
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-549
Revenue Forecast (FY)$12.40M
Bulls Say, Bears Say
Bulls Say
Focused Critical-care Biotech PipelineSpecialization in critical‑care and cardiopulmonary therapeutics is a durable strategic position: these are high‑unmet‑need areas with structural demand and limited crowded competition. A successful clinical advance could produce outsized long‑term returns relative to company size.
Ability To Access Capital For Strategic DealsIssuing senior convertible notes to fund an acquisition demonstrates the company can secure external financing and pursue M&A even with weak operations. Access to transactional capital supports strategic flexibility and potential inorganic growth over the medium term.
Lean Operating StructureA very small workforce indicates a lean cost base and focused R&D organization, which can extend runway per dollar of funding and enable nimble program management. For an early‑stage biotech, low overhead helps preserve capital for clinical priorities.
Bears Say
Negative Equity And Rising LeverageNegative equity and increased debt signal materially impaired balance‑sheet resilience. With equity deficit and higher leverage, the company faces elevated insolvency, refinancing and dilution risks, reducing financial flexibility to fund clinical programs long term.
Persistent, Sizable Cash BurnSustained negative operating and free cash flow of roughly -$15M TTM indicates ongoing dependence on external financing. Continuous cash burn threatens program continuity and increases the probability of dilutive financings or project delays over the next several quarters.
Recent Sudden Executive DepartureAn abrupt exit of the President/COO creates strategic and execution risk at a sensitive time for an R&D‑centric company. Leadership turnover can delay decision making, complicate fundraising and partnerships, and reduce continuity in clinical program execution.
Windtree Therapeutics News
WINT FAQ
What was Windtree Therapeutics’s price range in the past 12 months?
Windtree Therapeutics lowest stock price was <$0.01 and its highest was $3.48 in the past 12 months.
What is Windtree Therapeutics’s market cap?
Windtree Therapeutics’s market cap is $444.96K.
When is Windtree Therapeutics’s upcoming earnings report date?
Windtree Therapeutics’s upcoming earnings report date is Apr 08, 2026 which is in 35 days.
How were Windtree Therapeutics’s earnings last quarter?
Windtree Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.085 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.085.
Is Windtree Therapeutics overvalued?
According to Wall Street analysts Windtree Therapeutics’s price is currently Overvalued.
Does Windtree Therapeutics pay dividends?
Windtree Therapeutics does not currently pay dividends.
What is Windtree Therapeutics’s EPS estimate?
Windtree Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Windtree Therapeutics have?
Windtree Therapeutics has 33,708,782 shares outstanding.
What happened to Windtree Therapeutics’s price movement after its last earnings report?
Windtree Therapeutics reported an EPS of -$1.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Windtree Therapeutics?
Currently, no hedge funds are holding shares in WINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Windtree Therapeutics
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Technical Analysis
Theriva Biologics
―
Indaptus Therapeutics
―
Enveric Biosciences
―
Artelo Biosciences
―
Azitra Inc
―